Gilead Viread Adds Boxed Warning Regarding Hepatitis B Co-Infection
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients co-infected with HBV and HIV should be monitored for hepatic problems “for at least several months” if they discontinue Viread treatment. Labeling update also includes precautions about interactions with Abbott’s Kaletra and Bristol’s Reyataz.